20.06.2012 - The Danish small molecule lead discovery SME has raised enough money for international expansion, with planned operations in Sweden.
Copenhagen – In the past Nuevolution A/S from Copenhagen planned to expand operations in Sweden also. Now the Danish drug discovery company has the money to do so. On June 19, the enterprise announced that it had raised €11m in a new financing round. Jonas Brambeck, investment manager of the VC enterprise Industriefonden, said that "Nuevolution has shown the commercial use of their proprietary and innovative technology. The planned expansion in Sweden adds attractiveness to the investment." Besides that, Industrifonden has again involved investors Sunstone Capital, SEB Venture Capital and SEB Utvecklingsstiftelse in this round.
Nuevolution is situated in the Danish-Swedish biotech cluster Medicon Valley. Founded in 2001, the company quickly became a major developer of small molecule drugs. It owns a library collection of more than 1 billion small molecules and synthetic biologics. Using this biobank and its very own Chemetics® drug discovery platform, Nuevolution successfully screened for substances for companies like Merck & Co., GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. The Chemetics® technology is especially useful when it comes down to the discovery of difficult-to-address protein-protein interactions. Based on a DNA labelling of their small molecule compounds, the method allows fast and cheap screening.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.